The authors demonstrated that in patients with HER2-negative BRCA-positive tumor after local therapy and neoadjuvant or adjuvant chemotherapy, adjuvant therapy with olaparib was superior to placebo in terms of reducing mortality (p = 0.02), disease- (p < 0.001), and distant free survival (p < 0.001) [4]. Here, ERBB2 is linked to neoplasm.